Dexasone

Lymphoid Leukemia

St. Jude Children's Research HospitalSmall moleculePhase 2Dormant

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 89/ 100

Competitive context

13 Active assets in the Lymphoid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Dartmouth-Hitchcock Medical Center	Phase 4	BBB
Ibrutinib Loxo Oncology, Inc.	Phase 4	BBB
Busulfanum Dartmouth-Hitchcock Medical Center	Phase 4	BB
Pirtobrutinib Loxo Oncology, Inc.	Phase 3	BB
Lenalidomide University of Wisconsin, Madison	Phase 2	BB

View all 50 →

Same molecule, other indications

Dexasone is also rated in:

chemotherapy-induced toxicityActive

A

Indicative · Phase 4

82 / 100

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.